Ipsen appoints former Sanofi Pasteur Vaccines head as CEO

29 May 2020
ipsen-logo-big

French drugmaker Ipsen (Euronext: IPN), which has been under interim management since the surprise departure of its chief executive David Meek in December last year, today announced it has appointed David Loew as its new CEO and as board member. The CEO appointment will take effect on July 1, 2020.

The Ipsen board of directors expresses its gratitude to Aymeric Le Chatelier, who steered the group very well in an exceptionally challenging environment and who will remain in the role of acting CEO until July 1, 2020 and will continue in his role of chief financial officer.

Mr Loew, a Swiss citizen, will be based at Ipsen's headquarters in Boulogne-Billancourt, France. His mission will be to ensure Ipsen's continued growth and to advance its pipeline via a long-term value-adding external innovation strategy, while fostering a culture of entrepreneurship, agility and patient centricity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology